Omaha, NE – Streck, Inc., introduces CD-Chex™ CD117, the first and only commercially available flow
cytometry control for CD117.

CD-Chex 117 eliminates the need for laboratories to hold and validate patient samples to use as a
control for CD117, saving time and money.

CD-Chex CD117 is designed to represent abnormal peripheral blood leukocytes similar to a
hematolymphoid neoplastic patient sample. The product possesses surface CD117 that is detectable
with fluorescent monoclonal antibodies by flow cytometry. The CD117 positive abnormal leukocytes are
distinguishable from normal leukocytes on the basis of light scatter properties, a low level of CD45
expression and heterogeneous CD117 expression.

CD-Chex CD117 features 30-day open-vial stability and 90-day closed-vial stability.

For Research Use Only. Not for use in diagnostic procedures.

Streck also offers CD-Chex™ Plus, a positive procedural control for monitoring immunophenotyping by
flow cytometry. It provides the most assayed CD markers in the industry on a single control, including
those on the HIV panel of markers and a normal level of CD34+ cells. CD-Chex Plus is manufactured from
normal human peripheral blood leukocytes and erythrocytes and is available in two clinically relevant
levels of CD4+ cells.

About Streck, Inc.
Streck is an industry leader in the development and manufacturing of products for clinical and research laboratories. The company’s pursuit of innovative solutions has produced an extensive list of patented products. Streck’s core technology is cell stabilization; product lines support the fields of hematology, immunology and molecular diagnostics. For more information, visit

What we offer

Upcoming Events >